METABOLIC CHARACTERISTICS OF PATIENTS WITH OBESITY

Background: Obesity is considered to be the most wide-spared disease all over the world [1]. Having a hormonal activity, adipose tissue takes part in coordinating of metabolic processes. Taking into consideration the excess accumulation of the adipose tissue, the proceeding of metabolic process gets abidingly broken [2]. Aims: The aim of this thesis is to analyze a hormone metabolism of the hormones of adipose tissue among the patients who has obesity. Materials and methods: 30 patients with obesity without any accompanying disease were examined. This examination was done to determine the level of adipokines (leptin, adiponectin, visfatin), insulin with index calculus of insulin resistance, blood lipids. Results: The analysis showed the fact that patients with obesity have a higher level of insulin, leptin in comparison to the control group. However, the level of adiponectin among people from the control group increased the same level of patients with obesity. The essential differences in the level of visfatin has not been discovered. Hyperinsulinemia and Dyslipidemia (increased cholesterol low density lipoprotein (TC-LDL), triglycerides (TG), reduction of cholesterol of high density lipoproteins (HDL – C)) are observed alongside the increase of leptin level among the patients with obesity. Conclusion: Multidirectional changes of hormones of adipose tissue are established among the patients with obesity without somatic pathology in comparison with the ones without obesity and overweight. The determined dynamics of adipokines contributes changes of functioning of physiological systems of out organism and demands the research of more informative and essential methods of correction.

оbesity, adipokines, leptin, adiponectin, visfatin

1. World Health Organization. DOI: http://www.who.int/mediacentre/ factsheets/fs311/ru/ (дата обращения: 20.10.2017).

2. Кроненберг Г.М., Мелмед Ш., Полонски К.С., Ларсен П.Р. Ожирение и нарушения липидного обмена. Пер. с англ. М.: Рид Элсивер, 2010, 264 с.

3. Rasouli N, Kern PA. Adipocytokines and the Metabolic Complications of Obesity. The Journal of Clinical Endocrinology & Metabolism, 2008, 93(11_supplement_1): 64-73. DOI: 10.1210/jc.2008-1613.

4. Косыгина А.В. Адипоцитокины в научной и клинической практике. Ожирение и метаболизм, 2011, 1(26): 32-39.

5. Yadav A, Kataria MA, Saini V. Role of leptin and adiponectin in insulin resistance. Clin. Chim. Acta, 2013, 417: 80-84.

6. Baratta R, Amato S, Degano C et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J. Clin. Endocrinol. Metab., 2004, 89: 2665-2671.

7. Fasshauer M, Blbher M. Adipokines in health and disease. Trends Pharmacol. Sci., 2015, 36(7): 461-470.

8. Berndt J, Kloting N, Kralisch S et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes, 205, 54: 2911-2916.

9. Fukuhara A, Matsuda M, Nishizawa M et al. (2005). Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 2005, 307: 426-430.